Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity, ptinews.com
- August 21, 2024
Indoco Remedies receives final ANDA approval from the USFDA for Lofexidine Tablets 0.18 mg, indianpharmapost.com
- August 21, 2024
Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity, economictimes.indiatimes.com
- August 21, 2024
Indoco Remedies Gets US FDA Approval For Opioids drug, ndtvprofit.com
- August 21, 2024
USFDA gives nod to Indoco Remedies to market generic formulation for withdrawal treatment, financialexpress.com
- August 21, 2024
Indoco Remedies stock soars over 5% on USFDA approval for opioids drug, business-standard.com
- August 21, 2024
Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity, zeebiz.com
- August 21, 2024
Indoco gains final ANDA approval for Lofexidine Tablets 0.18 mg, expresspharma.in
- August 21, 2024
Indoco Remedies receives USFDA approval for Lofexidine Tablets 0.18 mg, business-standard.com
- August 21, 2024
Indoco Remedies Receives 'Hold' Rating from MarketsMOJO, Shows Neutral Outlook, Marketsmojo.com
- August 21, 2024
Indoco Remedies receives US FDA final approval to market generic Lucemyra tablets, pharmabiz.com
- August 21, 2024
Indoco Remedies receives USFDA approval for Lofexidine Tablets 0.18 mg capitalmarket.com
- August 21, 2024
Indoco Remedies climbs on getting USFDA’s final approval for Lofexidine Tablets investmentguruindia.com
- August 21, 2024
Indoco receives nod for exidine Tablets, The Navhind Times, Goa
- August 22, 2024